Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases.
Thompson LD.
Am J Surg Pathol. 2002 May;26(5):551-66. doi: 10.1097/00000478-200205000-00002.
Pheochromocytoma.
Farrugia FA, Charalampopoulos A.
Endocr Regul. 2019 Jul 1;53(3):191-212. doi: 10.2478/enr-2019-0020.
Malignant pheochromocytoma: a review.
Harari A, Inabnet WB 3rd.
Am J Surg. 2011 May;201(5):700-8. doi: 10.1016/j.amjsurg.2010.04.012. Epub 2010 Sep 27.
Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials.
Roman-Gonzalez A, Jimenez C.
Curr Opin Endocrinol Diabetes Obes. 2017 Jun;24(3):174-183. doi: 10.1097/MED.0000000000000330.
Pheochromocytoma: presentation, diagnosis and treatment.
Reisch N, Peczkowska M, Januszewicz A, Neumann HP.
J Hypertens. 2006 Dec;24(12):2331-9. doi: 10.1097/01.hjh.0000251887.01885.54.
Metastatic Pheochromocytomas and Abdominal Paragangliomas.
Granberg D, Juhlin CC, Falhammar H.
J Clin Endocrinol Metab. 2021 Apr 23;106(5):e1937-e1952. doi: 10.1210/clinem/dgaa982.
Treatment of malignant pheochromocytoma.
Adjallé R, Plouin PF, Pacak K, Lehnert H.
Horm Metab Res. 2009 Sep;41(9):687-96. doi: 10.1055/s-0029-1231025. Epub 2009 Aug 11.
Phaeochromocytoma.
Lenders JW, Eisenhofer G, Mannelli M, Pacak K.
Lancet. 2005 Aug 20-26;366(9486):665-75. doi: 10.1016/S0140-6736(05)67139-5.
Malignant pheochromocytoma: current status and initiatives for future progress.
Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, Giordano TJ, Greene LA, Goldstein DS, Lehnert H, Manger WM, Maris JM, Neumann HP, Pacak K, Shulkin BL, Smith DI, Tischler AS, Young WF Jr.
Endocr Relat Cancer. 2004 Sep;11(3):423-36. doi: 10.1677/erc.1.00829.
Changing paradigms in the treatment of malignant pheochromocytoma.
Grogan RH, Mitmaker EJ, Duh QY.
Cancer Control. 2011 Apr;18(2):104-12. doi: 10.1177/107327481101800205.
